vs
Intellia Therapeutics, Inc.（NTLA）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Intellia Therapeutics, Inc.的1.5倍（$35.5M vs $23.0M），RECURSION PHARMACEUTICALS, INC.净利率更高（-304.2% vs -416.2%，领先111.9%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 78.8%），RECURSION PHARMACEUTICALS, INC.自由现金流更多（$-47.3M vs $-69.4M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -10.8%）
Intellia Therapeutics是美国临床阶段生物技术企业，专注于依托CRISPR技术开发具有潜在治愈效果的创新疗法。公司体内项目采用静脉注射CRISPR疗法，通过专属递送技术可在特定靶组织内精准编辑致病基因；体外项目则利用CRISPR改造细胞制备治疗产品，主攻未被满足的医疗需求。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
NTLA vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.0M | $35.5M |
| 净利润 | $-95.8M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -428.9% | -304.8% |
| 净利率 | -416.2% | -304.2% |
| 营收同比 | 78.8% | 681.7% |
| 净利润同比 | 25.7% | 39.6% |
| 每股收益（稀释后） | $-0.81 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $23.0M | $35.5M | ||
| Q3 25 | $13.8M | $5.2M | ||
| Q2 25 | $14.2M | $19.2M | ||
| Q1 25 | $16.6M | $14.7M | ||
| Q4 24 | $12.9M | $4.5M | ||
| Q3 24 | $9.1M | $26.1M | ||
| Q2 24 | $7.0M | $14.4M | ||
| Q1 24 | $28.9M | $13.8M |
| Q4 25 | $-95.8M | $-108.1M | ||
| Q3 25 | $-101.3M | $-162.3M | ||
| Q2 25 | $-101.3M | $-171.9M | ||
| Q1 25 | $-114.3M | $-202.5M | ||
| Q4 24 | $-128.9M | $-178.9M | ||
| Q3 24 | $-135.7M | $-95.8M | ||
| Q2 24 | $-147.0M | $-97.5M | ||
| Q1 24 | $-107.4M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | -428.9% | -304.8% | ||
| Q3 25 | -808.9% | -3327.6% | ||
| Q2 25 | -772.2% | -916.8% | ||
| Q1 25 | -726.6% | -1297.9% | ||
| Q4 24 | -1059.9% | -4042.4% | ||
| Q3 24 | -1589.0% | -377.1% | ||
| Q2 24 | -1998.6% | -697.4% | ||
| Q1 24 | -394.0% | -698.4% |
| Q4 25 | -416.2% | -304.2% | ||
| Q3 25 | -735.2% | -3135.3% | ||
| Q2 25 | -710.8% | -894.2% | ||
| Q1 25 | -687.6% | -1373.3% | ||
| Q4 24 | -1001.2% | -3935.5% | ||
| Q3 24 | -1489.5% | -367.5% | ||
| Q2 24 | -2112.6% | -676.6% | ||
| Q1 24 | -371.3% | -662.4% |
| Q4 25 | $-0.81 | $-0.17 | ||
| Q3 25 | $-0.92 | $-0.36 | ||
| Q2 25 | $-0.98 | $-0.41 | ||
| Q1 25 | $-1.10 | $-0.50 | ||
| Q4 24 | $-1.27 | $-0.56 | ||
| Q3 24 | $-1.34 | $-0.34 | ||
| Q2 24 | $-1.52 | $-0.40 | ||
| Q1 24 | $-1.12 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $449.9M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $671.4M | $1.1B |
| 总资产 | $842.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $449.9M | $743.3M | ||
| Q3 25 | $511.0M | $659.8M | ||
| Q2 25 | $459.7M | $525.1M | ||
| Q1 25 | $503.7M | $500.5M | ||
| Q4 24 | $601.5M | $594.4M | ||
| Q3 24 | $658.1M | $427.6M | ||
| Q2 24 | $691.1M | $474.3M | ||
| Q1 24 | $791.3M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $671.4M | $1.1B | ||
| Q3 25 | $748.4M | $1.0B | ||
| Q2 25 | $715.3M | $919.1M | ||
| Q1 25 | $779.9M | $933.9M | ||
| Q4 24 | $872.0M | $1.0B | ||
| Q3 24 | $962.6M | $524.6M | ||
| Q2 24 | $971.1M | $584.4M | ||
| Q1 24 | $1.0B | $401.2M |
| Q4 25 | $842.1M | $1.5B | ||
| Q3 25 | $925.3M | $1.4B | ||
| Q2 25 | $898.9M | $1.3B | ||
| Q1 25 | $986.2M | $1.3B | ||
| Q4 24 | $1.2B | $1.4B | ||
| Q3 24 | $1.2B | $726.5M | ||
| Q2 24 | $1.2B | $775.9M | ||
| Q1 24 | $1.3B | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-69.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-69.4M | $-47.3M |
| 自由现金流率自由现金流/营收 | -301.6% | -133.1% |
| 资本支出强度资本支出/营收 | 0.5% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-395.9M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $-69.3M | $-46.1M | ||
| Q3 25 | $-76.9M | $-117.4M | ||
| Q2 25 | $-99.6M | $-76.4M | ||
| Q1 25 | $-148.9M | $-132.0M | ||
| Q4 24 | $-85.2M | $-115.4M | ||
| Q3 24 | $-84.8M | $-59.2M | ||
| Q2 24 | $-58.2M | $-82.2M | ||
| Q1 24 | $-120.7M | $-102.3M |
| Q4 25 | $-69.4M | $-47.3M | ||
| Q3 25 | $-76.9M | $-117.6M | ||
| Q2 25 | $-99.9M | $-79.6M | ||
| Q1 25 | $-149.7M | $-133.8M | ||
| Q4 24 | $-86.2M | $-116.7M | ||
| Q3 24 | $-86.1M | $-63.8M | ||
| Q2 24 | $-59.2M | $-83.4M | ||
| Q1 24 | $-123.2M | $-109.0M |
| Q4 25 | -301.6% | -133.1% | ||
| Q3 25 | -558.2% | -2272.5% | ||
| Q2 25 | -701.0% | -413.9% | ||
| Q1 25 | -900.1% | -907.4% | ||
| Q4 24 | -669.4% | -2567.7% | ||
| Q3 24 | -945.2% | -244.6% | ||
| Q2 24 | -850.9% | -578.5% | ||
| Q1 24 | -425.7% | -789.9% |
| Q4 25 | 0.5% | 3.5% | ||
| Q3 25 | 0.2% | 4.7% | ||
| Q2 25 | 1.7% | 16.4% | ||
| Q1 25 | 4.4% | 12.4% | ||
| Q4 24 | 7.6% | 28.6% | ||
| Q3 24 | 14.0% | 17.5% | ||
| Q2 24 | 14.5% | 8.2% | ||
| Q1 24 | 8.7% | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
RXRX
暂无分部数据
